The role of pharmacogenomics in improving the management of asthma

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 2, 2010, Pages 295-302

  Kazani, Shamsah ^a   Wechsler, Michael E ^a   Israel, Elliot ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C1; ADENYLATE CYCLASE; ARGININE; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; GLYCINE; IMMUNOGLOBULIN E RECEPTOR; LEUKOTRIENE C4 SYNTHASE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; SALBUTAMOL; STEROID; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG;

ASTHMA; GENE DELETION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; HUMAN; NONSYNONYMOUS SINGLE NUCLEOTIDE POLYMORPHISM; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STEROID THERAPY; SYNONYMOUS SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE;

ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; PHARMACOGENETICS;

EID: 75849156308     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.12.014     Document Type: Review

References (56)

1. Szefler S.J., Martin R.J., King T.S., Boushey H.A., Cherniack R.M., Chinchilli V.M., et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 109 (2002) 410-418
2. Israel E., Banerjee T.R., Fitzmaurice G.M., Kotlov T.V., LaHive K., and LeBoff M.S. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 345 (2001) 941-947
3. Szefler S.J., Phillips B.R., Martinez F.D., Chinchilli V.M., Lemanske R.F., Strunk R.C., et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 115 (2005) 233-242
4. Palmer L.J., Silverman E.S., Weiss S.T., and Drazen J.M. Pharmacogenetics of asthma. Am J Respir Crit Care Med 165 (2002) 861-866
5. Van Eerdewegh P., Little R.D., Dupuis J., Del Mastro R.G., Falls K., Simon J., et al. Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 418 (2002) 426-430
6. Hansen N.T., Brunak S., and Altman R.B. Generating genome-scale candidate gene lists for pharmacogenomics. Clin Pharmacol Ther 86 (2009) 183-189
7. Hawkins G.A., Tantisira K., Meyers D.A., Ampleford E.J., Moore W.C., Klanderman B., et al. Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med 174 (2006) 1101-1109
8. Weiss S.T., Litonjua A.A., Lange C., Lazarus R., Liggett S.B., Bleecker E.R., et al. Overview of the pharmacogenetics of asthma treatment. Pharmacogenomics J 6 (2006) 311-326
9. Green S.A., Cole G., Jacinto M., Innis M., and Liggett S.B. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 268 (1993) 23116-23121
10. Green S.A., Turki J., Innis M., and Liggett S.B. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 33 (1994) 9414-9419
11. Green S.A., Turki J., Bejarano P., Hall I.P., and Liggett S.B. Influence of beta(2)-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 13 (1995) 25-33
12. McGraw D.W., Forbes S.L., Kramer L.A., and Liggett S.B. Polymorphisms of the 5' leader cistron of the human beta 2-adrenergic receptor regulate receptor expression. J Clin Invest 102 (1998) 1927-1932
13. Panebra A., Schwarb M.R., Swift S.M., Weiss S.T., Bleecker E.R., Hawkins G.A., et al. Variable-length poly-C tract polymorphisms of the beta2-adrenergic receptor 3'-UTR alter expression and agonist regulation. Am J Physiol Lung Cell Mol Physiol 294 (2008) L190-L195
14. Anderson W., Bacanu S.A., Bleecker E.R., Meyers D., Emmett A., Yancey S., et al. A prospective haplotype analysis of beta2-adrenergic receptor polymorphisms and clinical response to salmeterol and salmeterol/fluticasone propionate. [abstract]. Am J Respir Crit Care Med 177 (2008) A775
15. Martinez F.D., Graves P.E., Baldini M., Solomon S., and Erickson R. Association between genetic polymorphisms of the beta 2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 100 (1997) 3184-3188
16. Lima J.J., Thomason D.B., Mohamed M.H., Eberle L.V., Self T.H., and Johnson J.A. Impact of genetic polymorphisms of the beta 2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 65 (1999) 519-525
17. Israel E., Chinchilli V.M., Ford J.G., Boushey H.A., Cherniack R., Craig T.J., et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 364 (2004) 1505-1512
18. Silverman E.K., Kwiatkowski D.J., Sylvia J.S., Lazarus R., Drazen J.M., Lange C., et al. Family-based association analysis of beta2-adrenergic receptor polymorphisms in the childhood asthma management program. J Allergy Clin Immunol 112 (2003) 870-876
19. Taylor D.R., Epton M.J., Kennedy M.A., Smith A.D., Iles S., Miller A.L., et al. Bronchodilator response in relation to beta2-adrenoceptor haplotype in patients with asthma. Am J Respir Crit Care Med 172 (2005) 700-703
20. Hall I.P., Blakey J.D., Al Balushi K.A., Wheatley A., Sayers I., Pembrey M.E., et al. Beta2-adrenoceptor polymorphisms and asthma from childhood to middle age in the British 1958 birth cohort: a genetic association study. Lancet 368 (2006) 771-779
21. Tsai H.J., Shaikh N., Kho J.Y., Battle N., Naqvi M., Navarro D., et al. Beta 2-adrenergic receptor polymorphisms: pharmacogenetic response to bronchodilator among African American asthmatics. Hum Genet 119 (2006) 547-557
22. Choudhry S., Ung N., Avila P.C., Ziv E., Nazario S., Casal J., et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med 171 (2005) 563-570
23. Carroll C.L., Stoltz P., Schramm C.M., and Zucker A.R. Beta2-adrenergic receptor polymorphisms affect response to treatment in children with severe asthma exacerbations. Chest 135 (2009) 1186-1192
24. Martin A.C., Zhang G., Rueter K., Khoo S.K., Bizzintino J., Hayden C.M., et al. Beta2-adrenoceptor polymorphisms predict response to beta2-agonists in children with acute asthma. J Asthma 45 (2008) 383-388
25. Israel E., Drazen J.M., Liggett S.B., Boushey H.A., Cherniack R.M., Chinchilli V.M., et al. The effect of polymorphisms of the beta2-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 162 (2000) 75-80
26. Taylor D.R., Drazen J.M., Herbison G.P., Yandava C.N., Hancox R.J., and Town G.I. Asthma exacerbations during long term beta-agonist use: influence of beta2 adrenoceptor polymorphism. Thorax 55 (2000) 762-767
27. Litonjua A.A., Silverman E.K., Tantisira K.G., Sparrow D., Sylvia J.S., and Weiss S.T. Beta 2-adrenergic receptor polymorphisms and haplotypes are associated with airways hyperresponsiveness among nonsmoking men. Chest 126 (2004) 66-74
28. Nelson H.S., Weiss S.T., Bleecker E.R., Yancey S.W., and Dorinsky P.M. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 (2006) 15-26
29. Wechsler M.E., Lehman E., Lazarus S.C., Lemanske Jr. R.F., Boushey H.A., Deykin A., et al. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 173 (2006) 519-526
30. Lee D.K., Currie G.P., Hall I.P., Lima J.J., and Lipworth B.J. The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br J Clin Pharmacol 57 (2004) 68-75
31. Palmer C.N., Lipworth B.J., Lee S., Ismail T., Macgregor D.F., and Mukhopadhyay S. Arginine-16 {beta}2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax 61 (2006) 940-944
32. Bleecker E.R., Postma D.S., Lawrance R.M., Meyers D.A., Ambrose H.J., and Goldman M. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 370 (2007) 2118-2125
33. Bleecker E.R., Yancey S.W., Baitinger L.A., Edwards L.D., Klotsman M., Anderson W.H., et al. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 118 (2006) 809-816
34. Bleecker E.R., Nelson H., Corren J., Kraft M., Yancey S., Ortega H., et al. Arg16Gly polymorphism of the β2-adrenergic receptor gene does not modulate clinical response to salmeterol in subjects with asthma. J Allergy Clin Immunol 121 suppl 1 (2008) S143
35. Wechsler M.E., Kunselman S.J., Chinchilli V.M., Bleeker E., Boushey H.A., Calhounb W.J., et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet 374 (2009) 1754-1764
36. Litonjua A.A., Lasky-Su J., Schneiter K., Tantisira K.G., Lazarus R., Klanderman B., et al. ARG1 is a novel bronchodilator response gene: screening and replication in four asthma cohorts. Am J Respir Crit Care Med 178 (2008) 688-694
37. Malmstrom K., Rodriguez-Gomez G., Guerra J., Villaran C., Pineiro A., Wei L.X., et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. Ann Intern Med 130 (1999) 487-495
38. Sampson A.P., Siddiqui S., Buchanan D., Howarth P.H., Holgate S.T., Holloway J.W., et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 55 suppl 2 (2000) S28-S31
39. Sanak M., Simon H.-U., and Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 350 (1997) 1599-1600
40. Sanak M., Pierzchalska M., Bazan-Socha S., and Szcezklik A. Enhanced expression of the leukotriene C4 synthase due to overactive transcription of an allelic variant associated with aspirin-intolerant asthma. Am J Respir Cell Mol Biol 23 (2000) 290-296
41. Whelan G.J., Blake K., Kissoon N., Duckworth L.J., Wang J., Sylvester J.E., et al. Effect of montelukast on time-course of exhaled nitric oxide in asthma: influence of LTC4 synthase A(-444)C polymorphism. Pediatr Pulmonol 36 (2003) 413-420
42. Asano K., Shiomi T., Hasegawa N., Nakamura H., Kudo H., Matsuzaki T., et al. Leukotriene C4 synthase gene A(-444)C polymorphism and clinical response to a CYS-LT(1) antagonist, pranlukast, in Japanese patients with moderate asthma. Pharmacogenetics 12 (2002) 565-570
43. Lima J.J., Zhang S., Grant A., Shao L., Tantisira K.G., Allayee H., et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med 173 (2006) 379-385
44. Drazen J.M., Yandava C.N., Dube L., Szczerback N., Hippensteel R., Pillari A., et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 22 (1999) 168-170
45. Telleria J.J., Blanco-Quiros A., Varillas D., Armentia A., Fernandez-Carvajal I., Jesus Alonso M., et al. ALOX5 promoter genotype and response to montelukast in moderate persistent asthma. Respir Med 102 (2008) 857-861
46. Klotsman M., York T.P., Pillai S.G., Vargas-Irwin C., Sharma S.S., van den Oord E.J., et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics 17 (2007) 189-196
47. Tantisira K.G., Lima J., Sylvia J., Klanderman B., and Weiss S.T. 5-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci. Pharmacogenet Genomics 19 (2009) 244-247
48. Mougey E.B., Feng H., Castro M., Irvin C.G., and Lima J.J. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics 19 (2009) 129-138
49. Tantisira K.G., Lake S., Silverman E.S., Palmer L.J., Lazarus R., Silverman E.K., et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet 13 (2004) 1353-1359
50. Dijkstra A., Koppelman G.H., Vonk J.M., Bruinenberg M., Schouten J.P., and Postma D.S. Pharmacogenomics and outcome of asthma: no clinical application for long-term steroid effects by CRHR1 polymorphisms. J Allergy Clin Immunol 121 (2008) 1510-1513
51. Tantisira K.G., Hwang E.S., Raby B.A., Silverman E.S., Lake S.L., Richter B.G., et al. TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci U S A 101 (2004) 18099-18104
52. Tantisira K.G., Silverman E.S., Mariani T.J., Xu J., Richter B.G., Klanderman B.J., et al. FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma. J Allergy Clin Immunol 120 (2007) 1285-1291
53. Tantisira K.G., Small K.M., Litonjua A.A., Weiss S.T., and Liggett S.B. Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between beta-agonist and corticosteroid pathways. Hum Mol Genet 14 (2005) 1671-1677
54. Stallings S.C., Huse D., Finkelstein S.N., Crown W.H., Witt W.P., Maguire J., et al. A framework to evaluate the economic impact of pharmacogenomics. Pharmacogenomics 7 (2006) 853-862
55. Burchard E.G., Ziv E., Coyle N., Gomez S.L., Tang H., Karter A.J., et al. The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med 348 (2003) 1170-1175
56. Himes B.E., Wu A.C., Duan Q.L., Klanderman B., Litonjua A.A., Tantisira K., et al. Predicting response to short-acting bronchodilator medication using Bayesian networks. Pharmacogenomics 10 (2009) 1393-1412